SBIR/STTR Research Award
IMPROVED MRI CONTRAST AGENTS
Award amount
$185,313Program and phase
SBIR · Phase IAward year
2002Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- NANOPROBES INC
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- JK7BK6JL14M6
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
A new class of MRI contrast agents has been discovered and synthesized by Nanoprobes. Initial MRI animal studies showed excellent definition of some types of brain tumors, which were
undetectable with the commonly used agent, gadodiamide. Furthermore, initial
toxicity studies showed the agents to be non-toxic. One new agent was coupled
to antibodies and showed high delivery to antigen on bench tests, indicating
hope for development of targeted contrast agents for functional MRI. This
project will focus on continued development including chemical synthesis,
purification, chemical and magnetic characterization, in vivo animal studies,
and antibody targeting of the agents in vivo.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Combined Fluorescent and Gold Labeling Reagents
- Smaller, Brighter Probes for Correlative Super-resolution and Electron Microscopy
- Gold Nanoparticle Treatment of Glioma
- Luminescent metal complex probes for correlative microscopy
- Conductive Metallography for Serial Section Electron Microscopy at Nanometer Resolution
Research funding history
47 SBIR/STTR records share this UEI (1991–2025). Reported award amounts total $12,102,185. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services, National Science Foundation, Department of Energy